A Phase III Randomized
Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)
Not exact matches
Appearing in Lancet Oncology, long term results
of EORTC
trial 22921 with 10.4 years median follow - up show that 5 - FU (fluorouracil) based
adjuvant chemotherapy after preoperative (chemo)- radiotherapy for patients with cT3 - resectable T4 M0 rectal cancer does not improve survival or disease - free survival.
Results
of EORTC
trial 22921 show that compliance with
adjuvant chemotherapy was poor, and only 42.9 %
of the patients received the planned dose within the scheduled time frame.
EORTC
trial 22921 explored the value
of adding
chemotherapy to preoperative radiotherapy either concurrently, or as an
adjuvant, or both for patients with cT3 - resectable T4 M0 rectal cancer.
A Randomized, Phase III
Trial to Evaluate The Efficacy and Safety
of MK - 3475 (Pembrolizumab) as
Adjuvant Therapy for Triple Receptor - Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (yPN +) After Neoadjuvant
Chemotherapy
In the BEVERLY - 1 (UCBG - 0802)
trial we aimed to assess the addition
of bevacizumab to neoadjuvant and
adjuvant chemotherapy in the treatment
of patients with HER2 - negative inflammatory breast cancer.
Adjuvant radiation and
chemotherapy may be
of value for advanced cases; however, adequate clinical
trials have not been done in the dog or cat.